Q3 2025 Dr Reddy's Laboratories Ltd Earnings Call Transcript
Key Points
- Dr Reddy's Laboratories Ltd (RDY) reported a double-digit top line growth of 16% year-on-year, driven by strong performance across various segments.
- The company achieved its highest ever quarterly revenues and EBITDA in Q3 FY25, with EBITDA margins at 27.5%.
- Successful integration of the Nicotine Replacement Therapy (NRT) business contributed significantly to revenue growth.
- Dr Reddy's Laboratories Ltd (RDY) launched innovative products such as toripalimab and elobixibat, enhancing its portfolio in India.
- The company made progress in its biosimilars journey, securing marketing authorization for rituximab in the UK and filing denosumab in both the US and Europe.
- The gross profit margin decreased sequentially by 91 basis points, impacted by price erosion.
- SG&A expenses increased by 19% year-over-year, driven by higher logistics costs and investments in new business initiatives.
- The US generics business faced challenges with price erosion and competition, leading to a sequential decline in revenue.
- The India business experienced slower growth in the cardiac and gastrointestinal segments, impacting overall performance.
- The company received a Form 483 with seven observations from the US FDA inspection at its Hyderabad facility, indicating potential compliance issues.
Ladies and gentlemen, good day, and welcome to the Quarter 3 FY25 Earnings Conference Call of Dr. Reddy's Laboratories Limited. (Operator Instructions)
I now hand the conference over to Ms. Richa Periwal. Thank you, and over to you, ma'am.
'-- -
Thank you. A very good morning and good evening to all of you, and thank you for joining us today for the Dr. Reddy's Q3 FY25 Earnings Conference Call. We have with us the leadership team of Dr. Reddy's, comprising Mr. Erez Israeli, our CEO; Mr. M.V. Narasimham, our CFO; and the Investor Relations team.
Earlier today, we have released our results, and the same is also posted on our website. We will kick off today's call with MVN taking us through the financial highlights of the quarter. This will be followed by Erez sharing his thoughts on business performance, post which we'll open the forum for Q&A.
Please note that today
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
